Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

A Word Here, A Word There: IND Investigator Tweaks Blog After US FDA Untitled Letter

Executive Summary

OPDP's first 2019 letter cites problematic claims about an investigational PET drug; investigator's response was to adjust verb tenses and other wording in the blog post.

You may also be interested in...



YouTube Video Suggesting Livalo Is Safer Than Other Statins Is Dinged By US FDA

Kowa Pharmaceuticals' patient testimonials implying switch from statins to Livalo will reduce drug side effects are misleading, untitled letter says.

ParaGard TV Spot Misrepresents Contraceptive’s Risks, US FDA Says

‘Untitled’ letter is FDA's third in the past eighteen months to target promotions for women’s health products. In the case of advertisement for CooperSurgical's copper-containing intrauterine device, which is regulated as a drug, the agency took issue with distracting visuals and reliance on superimposed text.

Eskata Video Ad Broadcast On The View Gets Rebuke From US FDA

Agency says superimposed text about risks and efficacy is overshadowed by "attention-grabbing before-and-after photographs" of patients treated with the seborrheic keratoses treatment.

Related Content

Topics

UsernamePublicRestriction

Register

PS143249

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel